Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Connable Office Inc.

Connable Office Inc. increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,972 shares of the medical research company’s stock after acquiring an additional 37 shares during the period. Connable Office Inc.’s holdings in Amgen were worth $2,246,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of AMGN. M&G Plc acquired a new stake in Amgen during the first quarter valued at $7,633,000. Pinkerton Retirement Specialists LLC grew its position in shares of Amgen by 30.1% during the 1st quarter. Pinkerton Retirement Specialists LLC now owns 12,708 shares of the medical research company’s stock valued at $3,613,000 after acquiring an additional 2,943 shares during the period. Councilmark Asset Management LLC purchased a new position in shares of Amgen in the 1st quarter valued at about $2,891,000. Intech Investment Management LLC boosted its position in Amgen by 18.9% during the first quarter. Intech Investment Management LLC now owns 35,673 shares of the medical research company’s stock worth $10,143,000 after purchasing an additional 5,668 shares in the last quarter. Finally, Spirepoint Private Client LLC acquired a new stake in Amgen in the first quarter valued at approximately $1,110,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Down 1.8 %

AMGN stock opened at $295.93 on Friday. The firm has a market cap of $159.07 billion, a PE ratio of 37.89, a PEG ratio of 2.69 and a beta of 0.60. Amgen Inc. has a one year low of $260.52 and a one year high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The firm’s 50 day moving average price is $322.15 and its 200-day moving average price is $318.15.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.96 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.04%. Amgen’s dividend payout ratio is currently 115.24%.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. StockNews.com upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Sanford C. Bernstein assumed coverage on shares of Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective on the stock. Oppenheimer reissued an “outperform” rating and set a $380.00 target price on shares of Amgen in a research note on Wednesday, August 7th. UBS Group lowered their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Finally, Robert W. Baird reiterated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.